Business
Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year
Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, hereinafter referred to as "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months ended June 30, 2025. The Company achieved robust revenue growth of 31.7% year-over-year (YoY) to RMB 482 million, while net profit surged by 76.0% to exceed RMB 121 million, representing a net profit margin of 25.1%.
About this update from Zylox-tonbridge Medical Technology Co., Ltd. Class H
[{"type":"text","content":"HANGZHOU, China, Aug. 20, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, hereinafter referred to as "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months ended June 30, 2025. The Company achieved robust revenue growth of 31.7% year-over-year (YoY) to RMB 482 million, while net profit surged by 76.0% to exceed RMB 121 million, representing a net profit margin of 25.1%.","length":459,"tagName":"p"},{"type":"text","content":"In the first half of 2025, Zylox-Tonbridge maintained solid performance in its core neurovascular and peripheral vascular intervention businesses. Neurovascular product revenue reached RMB 304 million, up 25.0% YoY, while peripheral vascular product revenue climbed to RMB 176 million, a YoY increase of 46.2%. Driven by the Company's continuous focus on lean operations, combined R&D, selling, and administrative expenses as a percentage of revenue declined by 7 percentage points compared to the same period last year, further strengthening the Company's profitability profile.","length":591,"tagName":"p"},{"type":"text","content":"The Company's international business sustained strong growth in the first half of 2025, with revenue reaching RMB 15.72 million. By June 30, the Company had commercialized 22 products in 27 countries and regions, with over 31 products under registration in 23 markets. Its global network covers 52 countries and regions through partnerships with over 60 local distributors. With overseas commercialization accelerating and revenue contribution rising, the international business is becoming a new growth driver.","length":515,"tagName":"p"},{"type":"text","content":"Mature Portfolio Delivers Growth as Innovative Products Poised for Launch","length":73,"tagName":"p"},{"type":"text","content":"Leveraging a comprehensive and high-quality product portfolio and an efficient commercial team, Zylox-Tonbridge achieved strong sales growth in the first half of the year. Several VBP-selected products were successfully renewed under a more stable procurement environment, supporting continued market penetration and share gains.","length":329,"tagName":"p"},{"type":"text","content":"Sales of multiple flagship products, including the SilverSnake® Intermediate Catheter Series, neurovascular guidewires, Kyli...
More updates from Zylox-tonbridge Medical Technology Co., Ltd. Class H